Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the sale, the chief executive officer now directly owns 721,924 shares of the company’s stock, valued at $11,933,403.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.
• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.23, for a total transaction of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $12.32, for a total transaction of $51,362.08.

Centessa Pharmaceuticals Price Performance

CNTA opened at $16.58 on Friday. Centessa Pharmaceuticals plc has a twelve month low of $5.15 and a twelve month high of $17.59. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -11.68 and a beta of 1.44. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company has a fifty day simple moving average of $12.28 and a 200 day simple moving average of $10.64.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Equities research analysts expect that Centessa Pharmaceuticals plc will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CNTA has been the topic of several recent research reports. Jefferies Financial Group upped their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. B. Riley began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $33.00 target price for the company. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, BMO Capital Markets boosted their price objective on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.17.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $4,064,000. Perceptive Advisors LLC increased its stake in shares of Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock worth $35,518,000 after buying an additional 850,000 shares during the last quarter. Quarry LP raised its holdings in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares in the last quarter. Driehaus Capital Management LLC raised its holdings in Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after acquiring an additional 987,997 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Centessa Pharmaceuticals by 30.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company’s stock valued at $1,272,000 after acquiring an additional 32,846 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.